NASDAQ : STTK
Shattuck Labs, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 5.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 574.08M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 558.02M |
| Enterprise Value | 352.39M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 100.36M |
| Shares Outstanding | 100.36M |
| Shares Change (YoY) | +106.11% |
| Shares Change (QoQ) | +15.63% |
| Owned by Insiders (%) | 6.96% |
| Owned by Institutions (%) | 58.53% |
| Float | 67.76M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 558.02 |
| Forward PS | 2,264.78 |
| PB Ratio | 2.65 |
| P/TBV Ratio | 2.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 352.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 27.59 |
| Quick Ratio | 26.94 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -39.21% |
| Return on Assets (ROA) | -24.43% |
| Return on Invested Capital (ROIC) | -25.43% |
| Return on Capital Employed (ROCE) | -26.16% |
| Weighted Average Cost of Capital (WACC) | 10.24% |
| Revenue Per Employee | $25,000 |
| Profits Per Employee | -$1.31M |
| Employee Count | 40 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +185.13% |
| 50-Day Moving Average | 6.28 |
| 200-Day Moving Average | 6.04 |
| Relative Strength Index (RSI) | 43.20 |
| Average Volume (20 Days) | 1,108,919 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.44M |
| Short Previous Month | 10.95M |
| Short % of Shares Out | 10.40% |
| Short % of Float | 15.41% |
| Short Ratio (days to cover) | 6.45 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.00M |
| Gross Profit | -38.24M |
| Operating Income | -55.71M |
| Pretax Income | -52.57M |
| Net Income | -52.57M |
| EBITDA | -52.14M |
| EBIT | -55.71M |
| Loss Per Share | -$0.50 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 208.30M |
| Total Debt | 2.67M |
| Net Cash | 205.63M |
| Net Cash Per Share | $2.05 |
| Equity (Book Value) | 211.14M |
| Book Value Per Share | 2.10 |
| Working Capital | 205.54M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -41.03M |
| Capital Expenditures | -212,000 |
| Depreciation & Amortization | 3.57M |
| Net Borrowing | n/a |
| Free Cash Flow | -41.24M |
| FCF Per Share | -$0.41 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -5,570.50% |
| Pretax Margin | -5,256.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -106.11% |
| Shareholder Yield | -106.11% |
| Earnings Yield | -9.01% |
| FCF Yield | -7.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.40 |
| Price Target Difference | 176.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | -50.00% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 13.3 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |